Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.

Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.

The highly immunogenic human tumor antigen NY-ESO-1 (ESO) is a target of choice for anti-cancer immune therapy. In this study, we assessed spontaneous antibody (Ab) responses to ESO in a large cohort of patients with primary breast cancer (BC) and addressed the correlation between the presence of an...

Full description

Bibliographic Details
Main Authors:	Ahmed Hamaï, Karine Duperrier-Amouriaux, Pascale Pignon, Isabelle Raimbaud, Lorenzo Memeo, Cristina Colarossi, Vincenzo Canzonieri, Tiziana Perin, Jean-Marc Classe, Mario Campone, Pascal Jézéquel, Loïc Campion, Maha Ayyoub, Danila Valmori
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2011-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3117860?pdf=render

Similar Items

NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.
by: Nassima Redjimi, et al.
Published: (2011-01-01)

Modulation of Cytokine Secretion Allows CD4 T Cells Secreting IL-10 and IL-17 to Simultaneously Participate in Maintaining Tolerance and Immunity.
by: Kanako Saito, et al.
Published: (2015-01-01)

Using modified antigenic sequences to develop cancer vaccines: are we losing the focus?
by: Danila Valmori, et al.
Published: (2004-11-01)

LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers
by: Knuth A, et al.
Published: (2004-07-01)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
by: Remy Thomas, et al.
Published: (2018-05-01)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
by: Wenjie Gong, et al.
Published: (2021-01-01)

Expressão do antígeno antitumorgênico NY-ESO-1 em plantas
by: Lima, Thaina de Almeida
Published: (2014)

Breast metastasis of primary colon cancer with micrometastasis in the axillary sentinel node: A metastasis that metastasized?
by: Massarut Samuele, et al.
Published: (2011-05-01)

Análise da expressão da proteína NY-ESO-1 no melanoma cutâneo
by: Mara Huffenbaecher Giavina-Bianchi
Published: (2016)

Análise da expressão da proteína NY-ESO-1 no melanoma cutâneo
by: Giavina-Bianchi, Mara Huffenbaecher
Published: (2016)

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells
by: Oscar L Haigh, et al.
Published: (2020-07-01)

612 Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells
by: Kelly-Anne Masterman, et al.
Published: (2020-11-01)

Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
by: Katy Milne, et al.
Published: (2008-01-01)

Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma
by: Mara Giavina-Bianchi, et al.
Published: (2015-01-01)

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients
by: Chiara Camisaschi, et al.
Published: (2018-10-01)

Prognostic impact of p53 and/or NY‐ESO‐1 autoantibody induction in patients with gastroenterological cancers
by: Isamu Hoshino, et al.
Published: (2020-05-01)

NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.
by: Foluso O Ademuyiwa, et al.
Published: (2012-01-01)

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
by: Indu Ramachandran, et al.
Published: (2019-10-01)

Plant Viral Nanoparticle-based Vaccine Targeting NY-ESO-1+ Triple Negative Breast Cancer
by: Patel, Bindi, Patel
Published: (2018)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
by: Foluso O. Ademuyiwa, et al.
Published: (2012-01-01)

A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.
by: Lisa M Ebert, et al.
Published: (2012-01-01)

MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma
by: T. Bujas, et al.
Published: (2011-03-01)

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
by: Afsheen Raza, et al.
Published: (2020-03-01)

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
by: Michael Lattanzi, et al.
Published: (2018-05-01)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer.
by: Foluso O. Ademuyiwa, et al.
Published: (2012-01-01)

Identification of NY-ESO-1157–165 Specific Murine T Cell Receptors With Distinct Recognition Pattern for Tumor Immunotherapy
by: Helin Zhang, et al.
Published: (2021-03-01)

Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor
by: Jocelyn Joseph, et al.
Published: (2019-11-01)

Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine.
by: Caroline Junqueira, et al.
Published: (2012-01-01)

Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway
by: Konkankit Veerauo V, et al.
Published: (2011-11-01)

Bedeutung der immunhistochemischen Expression von MAGE A3, NY-ESO 1 und STEAP-1 beim Harnblasenkarzinom
by: Braun, Klara
Published: (2018)

Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.
by: Tiphaine Delaunay, et al.
Published: (2018-03-01)

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
by: Mikiya Ishihara, et al.
Published: (2020-06-01)

Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells.
by: Anna Pagotto, et al.
Published: (2013-01-01)

Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status
by: Yasuo Shiohama, et al.
Published: (2017-07-01)

Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
by: Agnes S Klar, et al.
Published: (2015-01-01)

Eso es pedagogía
by: Alexandra Calandra
Published: (2007-04-01)

Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses
by: Yunkai Yang, et al.
Published: (2021-02-01)

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
by: Craig L. Slingluff, et al.
Published: (2021-01-01)

Expression of genes MAGE-A3 MAGE-C1, NY-ESO-1 and SSX1 in patients with multiple myeloma at the General Hospital of Mexico
by: A. De la Cruz-Rosas, et al.
Published: (2018-04-01)

Estabelecimento de uma nova terapia antitumoral utilizando parasito transgênico expressando NY-ESO-1 associado ao bloqueio de CTLA-4
by: Luara Isabela dos Santos
Published: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ik16g6g8p16blj7ffg3d5i36v2